Key Benefits

• See your inflammation-versus-protection balance using monocytes and HDL cholesterol.
• Spot early artery inflammation; higher MHR links to atherosclerosis and cardiac events.
• Clarify cardiometabolic risk; higher values track with diabetes, hypertension, and obesity burden.
• Guide lifestyle intensity; MHR often improves with weight loss, exercise, and HDL gains.
• Flag fatty liver risk; elevated MHR associates with fatty liver disease and fibrosis severity.
• Support reproductive health; emerging research links higher MHR to PCOS severity and preeclampsia.
• Track trends over time to gauge therapy impact and residual inflammatory risk.
• Best interpreted with complete blood count differential, HDL cholesterol, high-sensitivity CRP, full lipids, and symptoms.

What is a Monocyte-to-HDL Ratio (MHR) blood test?

Monocyte-to-HDL Ratio (MHR) blood testing calculates the proportion of monocytes to high-density lipoprotein in circulation. Monocytes (innate immune white blood cells) are made in the bone marrow and travel in the bloodstream before moving into tissues, where they can mature into macrophages. HDL (high-density lipoprotein, often called “good cholesterol”) consists of small, protein-rich particles produced mainly by the liver and intestine that ferry cholesterol through the blood.

MHR distills two biologic forces into one number: the body’s inflammatory drive versus its vascular protection. Monocytes can amplify inflammation and, after entering vessel walls, contribute to plaque development by becoming lipid-laden foam cells. HDL counters this by removing cholesterol from tissues (reverse cholesterol transport) and by exerting anti-inflammatory and antioxidant effects on the endothelium. As a result, MHR reflects the balance between pro-inflammatory cellular activity and protective lipid transport—an integrated snapshot of immune–lipid interplay relevant to vascular health. Because it combines common elements of a blood count and lipid profile, MHR offers a concise view of the milieu that favors or restrains atherosclerosis (arterial plaque formation).

Why is a Monocyte-to-HDL Ratio (MHR) blood test important?

The monocyte-to-HDL ratio (MHR) captures the tug-of-war between inflammatory white blood cells and the anti-inflammatory, endothelial-protective actions of HDL cholesterol. A higher ratio points to more immune activation relative to vascular cleanup and repair, flagging vessel wall stress, plaque activity, and broader cardiometabolic inflammation.

There is no single reference range; labs compute MHR differently. In healthy adults it tends to sit mid‑range, and lower within that band is generally more favorable. A low ratio from strong HDL with normal monocytes signals quiet inflammation and healthier endothelium, usually without symptoms. If very low because monocytes are below normal, it may indicate reduced innate immunity, with recurrent infections or slow wound healing.

A high ratio—via more monocytes and/or low HDL—indicates a pro‑inflammatory, pro‑atherogenic milieu. It aligns with endothelial dysfunction, plaque activity, insulin resistance, fatty liver, and kidney microvascular stress. Often silent, it can coexist with fatigue or metabolic‑syndrome features. Men generally run higher ratios than premenopausal women; after menopause values converge. In pregnancy, both HDL and monocytes shift, so pregnancy‑specific interpretation matters. In children and teens, developmental changes in immunity and lipids make context essential.

Big picture, MHR links immune tone with lipid transport and vascular repair. It complements CRP, neutrophil‑to‑lymphocyte ratio, LDL, triglycerides, HbA1c, and kidney measures, and higher values have been associated with greater long‑term cardiometabolic and atherosclerotic risk, while lower values suggest a more resilient vascular state.

What insights will I get?

What a Monocyte-to-HDL Ratio (MHR) blood test tells you

The MHR combines two counterbalancing signals: circulating monocytes (innate immune activity) divided by HDL cholesterol (anti-inflammatory and antioxidant capacity). It is a compact gauge of inflammatory load versus lipid “buffering,” relevant to vessel health, metabolic efficiency, cardiac risk, cognitive resilience, and overall recovery capacity.

Low values usually reflect fewer circulating monocytes and/or higher HDL. This points to a quieter innate immune tone with robust reverse cholesterol transport and oxidative stress control. In some cases, very low values can occur with reduced bone marrow output, recent glucocorticoid exposure, or immune suppression; in older adults this may parallel increased infection susceptibility. Premenopausal women often show lower MHR given typically higher HDL.

Being in range suggests balanced immune surveillance with adequate HDL-mediated cholesterol efflux, supporting endothelial stability, flexible vascular reactivity, and steadier metabolic signaling. Observational data generally associate the low-to-mid portion of the reference range with favorable cardiometabolic profiles.

High values usually reflect heightened monocyte-driven inflammation and/or low HDL, signaling reduced anti-inflammatory buffering. This milieu favors endothelial dysfunction, plaque formation, pro-thrombotic tendency, insulin resistance, fatty liver progression, and microvascular kidney stress. MHR often rises with acute infections and chronic inflammatory or cardiometabolic states; it tends to be higher with aging and after menopause as HDL declines. In pregnancy, monocytes increase and HDL shifts across trimesters, so MHR may transiently rise.

Notes: Interpretation is influenced by acute illness, recent strenuous exercise, smoking, and circadian timing. HDL is measured enzymatically and is minimally affected by fasting, while monocyte counts come from the CBC and vary with stress hormones. Medications that alter leukocytes or HDL (e.g., corticosteroids, immunosuppressants, estrogens, lipid-lowering agents) can shift MHR.